Aspen Neuroscience, Inc. Stock: price and insider trades · United States
2 insiders bought €31.3M of shares over the last 90 days, the latest by Thompson Peter A., filed 04 Nov 2026.
Cluster: 2 buyers in 30 daysAspen Neuroscience, Inc.: what insiders have been doing
This page follows insider dealings at Aspen Neuroscience, Inc. as filed with SEC (Form 4). Between 5 November 2025 and 5 November 2026, 5 insiders published 28 filings.
Every open-market trade in the period is a purchase: 4 purchases worth €31.3M, from 2 insiders, and not a single sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 major shareholder and 1 senior executive. Biggest ticket of the year: €16.1M, bought by ARCH Venture Fund X, L.P. and made public on 2 November 2026.
In the case of 4 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase is recent: it was published 4 days ago, on 4 November 2026. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
With 28 filings in twelve months, the company is more active than the median of 24 filings across the 3,179 companies we follow on the same exchange. Over the whole record (from 2026), the tally stands at 4 purchases and no sales.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 196,541 sharesCommon StockSEC:0000947871-26-000981:0
- 642,745 sharesCommon StockSEC:0000947871-26-000981:1
- 616,984 sharesCommon StockSEC:0000947871-26-000981:2
- 625,743 sharesCommon StockSEC:0000947871-26-000981:3
- 507,119 sharesCommon StockSEC:0000947871-26-000981:4
- 196,541 sharesCommon StockSEC:0000947871-26-000980:0
- 642,745 sharesCommon StockSEC:0000947871-26-000980:1
- 616,984 sharesCommon StockSEC:0000947871-26-000980:2
- 625,743 sharesCommon StockSEC:0000947871-26-000980:3
- 507,119 sharesCommon StockSEC:0000947871-26-000980:4
- 1,000,000 shares@ US$15.003.99% mcap100.0% of flowCommon StockSEC:0000947871-26-000981:5Canonical exit: 31 Jan 2027 (T+90)
- 1,000,000 shares@ US$15.003.99% mcap100.0% of flowCommon StockSEC:0000947871-26-000980:5Canonical exit: 31 Jan 2027 (T+90)
- 187,182 sharesCommon StockSEC:0001193125-26-444147:1
- 298,258 sharesCommon StockSEC:0001193125-26-444147:7
- 286,304 sharesCommon StockSEC:0001193125-26-444147:8
- 214,355 sharesCommon StockSEC:0001193125-26-444147:10
- 70,194 sharesCommon StockSEC:0001193125-26-444128:0
- 14,913 sharesCommon StockSEC:0001193125-26-444126:0
- 1,200,000 shares@ US$15.0090.0% of flowCommon StockSEC:0001193125-26-444147:11Canonical exit: 31 Jan 2027 (T+90)
- 298,258 sharesCommon StockSEC:0001193125-26-444147:2
- 286,304 sharesCommon StockSEC:0001193125-26-444147:3
- 295,490 sharesCommon StockSEC:0001193125-26-444147:4
- 259,948 sharesCommon StockSEC:0001193125-26-444147:5
- 295,490 sharesCommon StockSEC:0001193125-26-444147:9
- 180,221 sharesCommon StockSEC:0001193125-26-444128:1
25 of 30 declarations
About Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. is a company focused on developing therapies for neurodegenerative diseases. It is listed on the XNAS market.